Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study

• Published in: Vaccine Vol. 42; no. 13; pp. 3157 - 3165
• Main Authors: Matur, Ramesh V., Thuluva, Subhash, Gunneri, Subbareddy, Yerroju, Vijay, reddy Mogulla, Rammohan, Thammireddy, Kamal, Paliwal, Piyush, Mahantshetty, Niranjana S., Ravi, Mandyam Dhati, Prashanth, S., Verma, Savita, Narayan, Jai Prakash
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 10.05.2024; Elsevier Limited
• Subjects: Active control; Age groups; Allergy and Immunology; Aluminum; Antibodies; Antibodies, Bacterial - blood; Antigens; burden of disease; Capsular polysaccharides; clinical trials; Conjugate vaccine; Conjugates; cross immunity; Developing countries; Disease; Dosage; Drug dosages; Epidemiology; Fatalities; Female; Hepatitis; Humans; Immune response; Immune system; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Immunoglobulin G - blood; India; Infant; Infants; LDCs; Male; Meningitis; Opsonophagocytic activity; Pediatrics; Pneumococcal capsular polysaccharide; Pneumococcal disease; Pneumococcal Infections - immunology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - adverse effects; Pneumococcal Vaccines - immunology; Pneumonia; Polysaccharides; Proteins; Safety; Schedules; Serogroup; Serotype; Serotypes; Single-Blind Method; Streptococcus infections; Streptococcus pneumoniae; Streptococcus pneumoniae - immunology; Vaccines; Vaccines, Conjugate - administration & dosage; Vaccines, Conjugate - adverse effects; Vaccines, Conjugate - immunology; India; Opsonophagocytic activity; Conjugate vaccine; Infants; Pneumococcal disease; Serotype; Pneumococcal capsular polysaccharide; Streptococcus pneumoniae

Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing pneumococcal vaccines, particularly impacting pediatric and elder popu...